Erlotinib in non-small cell lung cancer (NSCLC): Interim safety analysis of the TRUST study
U Gatzemeier, A Ardizzoni, K Horwood… - Journal of Clinical …, 2007 - ascopubs.org
7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …
prolonged survival, delayed symptom progression, and improved quality of life versus …
From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy
F Mazzoni, V Rotella, N Pratesi, L Boni… - Tumori …, 2011 - journals.sagepub.com
Background Inhibition of the epidermal growth factor receptor pathway with tyro-sine kinase
inhibitors can improve outcome of patients with advanced non-small cell lung cancer after …
inhibitors can improve outcome of patients with advanced non-small cell lung cancer after …
Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and …
M Faehling, R Eckert, S Kuom, T Kamp, KM Stoiber… - Oncology, 2010 - karger.com
Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …
after failure of initial therapy. Patient selection based on clinical factors is under discussion …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - Wiley Online Library
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC)
U Jimenez, A Gurpide, D Isla… - Journal of Clinical …, 2007 - ascopubs.org
7639 Background: Erlotinib is an orally available selective EGFR tyrosine-kinase inhibitor.
Erlotinib is approved for the treatment of patients (p) with advanced or metastatic NSCL that …
Erlotinib is approved for the treatment of patients (p) with advanced or metastatic NSCL that …
Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
N Reguart, AF Cardona, R Rosell - Cancer management and …, 2010 - Taylor & Francis
Erlotinib hydrochloride (Tarceva®) is a member of a class of small molecule inhibitors that
targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti …
targets the tyrosine kinase domain of the epidermal growth factor receptor (EGFR), with anti …
Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients
B Piperdi, R Perez-Soler - Drugs, 2012 - Springer
Erlotinib is an orally administered small molecule inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
receptor (EGFR) tyrosine kinase. Erlotinib at the standard oral daily dose of 150 mg is …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …